Rybelsus Is Now “Ozempic Tablets”: What Changed and Why It Matters

Why the Rebrand?

“Ozempic” is one of the most recognized drug names in the world. It was Google’s most-searched health term in 2023 and 2024. “Rybelsus,” by comparison, has a fraction of that awareness despite being the same molecule in oral form. By renaming Rybelsus to Ozempic tablets, Novo Nordisk accomplishes several strategic objectives:

Instant brand recognition: Patients who know about Ozempic immediately understand what Ozempic tablets are. No separate marketing campaign needed to explain a medication most people have never heard of.

Simplified product line: Novo Nordisk’s semaglutide portfolio now follows a cleaner structure: Ozempic (injectable for diabetes), Ozempic tablets (oral for diabetes), and Wegovy (injectable and now oral, for weight loss). Each name maps clearly to an indication.

Competitive positioning: With orforglipron and other oral GLP-1s approaching the market, consolidating the Ozempic brand across delivery formats strengthens Novo Nordisk’s position in patients’ minds.

What Patients Need to Know

Your prescription: If you currently take Rybelsus, your prescription will transition to the Ozempic tablets name. Your prescriber and pharmacy will handle this. You don’t need a new prescription — the NDC (National Drug Code) may change, but the product is identical.

Your dosing: Nothing changes. The available doses (3mg, 7mg, 14mg) remain the same. The administration rules (empty stomach, small water, 30-minute fast) remain the same.

Your insurance: Formulary coverage should transfer from Rybelsus to Ozempic tablets, but it’s worth confirming with your insurer to avoid any gaps during the transition. Some formulary systems may take weeks to update their databases.

Your pharmacy: During the transition period, you may see either name on your prescription bottle. Both refer to the same medication.

Ozempic Tablets vs. Wegovy Pill: Clearing Up Confusion

The rebrand creates a potential confusion point: Ozempic tablets and the Wegovy pill are both oral semaglutide from Novo Nordisk. Here’s the critical distinction:

The doses are substantially different because the indications are different. Diabetes management requires lower semaglutide exposure than weight loss. If you’re interested in oral semaglutide for weight loss, the Wegovy pill (up to 50mg) is the appropriate product — not Ozempic tablets (max 14mg).

That said, some prescribers do prescribe Ozempic (or formerly Rybelsus) off-label for weight loss, particularly when insurance covers the diabetes indication but not the weight-loss indication. This practice — while legal — typically involves lower doses than the Wegovy pill’s weight-loss-optimized regimen.

The Bigger Picture: Novo Nordisk’s Oral Strategy

The Rybelsus-to-Ozempic-tablets rebrand is part of Novo Nordisk’s broader play to dominate the oral GLP-1 market before competitors arrive. With the Wegovy pill already launched at aggressive pricing and Ozempic tablets carrying the world’s most recognized GLP-1 brand name, Novo Nordisk enters the oral competition from a position of strength.

For the compounding market, the rebrand itself has no direct impact. But it signals Novo Nordisk’s commitment to expanding access and awareness of their oral products — which adds another competitive pressure on compounding providers.